Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
On Wednesday, China approved AstraZeneca plc's (NYSE:AZN) Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy for the 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 mutations. On Tuesday, the Tagrisso with pemetrexed and platinum-based chemotherapy regime received approval in Japan for the same indication. China's National
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released topline data from the ADJUVANT BR.31 Phase 3 trial, sponsored by the Canadian Cancer Trials Group. The data showed that Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer (NSCLC) after complete tumor resection in patients whose tumors express PD-L1 on 25% or more tumor cells. “We are disappointed in the ADJUVANT BR.31 results,” sa